{"id":"bevacizumab-pfizer","safety":{"commonSideEffects":[{"rate":"20–40%","effect":"Hypertension"},{"rate":"15–35%","effect":"Proteinuria"},{"rate":"15–25%","effect":"Hemorrhage (any grade)"},{"rate":"5–10%","effect":"Thrombotic events"},{"rate":"0.5–2%","effect":"Gastrointestinal perforation"},{"rate":"5–10%","effect":"Wound healing complications"},{"rate":"15–25%","effect":"Fatigue"},{"rate":"10–20%","effect":"Diarrhea"}]},"_chembl":{"chemblId":"CHEMBL1201583","moleculeType":"Antibody"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Bevacizumab binds to circulating VEGF, a key signaling protein that promotes angiogenesis (new blood vessel growth). By neutralizing VEGF, the drug inhibits the formation of new blood vessels that tumors require to grow and metastasize. This anti-angiogenic mechanism reduces tumor perfusion and can slow or halt tumor progression.","oneSentence":"Bevacizumab is a monoclonal antibody that blocks vascular endothelial growth factor (VEGF), preventing tumor blood vessel formation and starving tumors of oxygen and nutrients.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:04:05.618Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Metastatic colorectal cancer"},{"name":"Metastatic non-small cell lung cancer"},{"name":"Metastatic breast cancer"},{"name":"Recurrent glioblastoma"},{"name":"Metastatic renal cell carcinoma"},{"name":"Cervical cancer"}]},"trialDetails":[{"nctId":"NCT04126044","phase":"PHASE1","title":"A SINGLE-DOSE, 2-ARM, PHARMACOKINETIC STUDY OF PF-06439535 (CN) AND EUROPEAN UNION SOURCED BEVACIZUMAB IN CHINESE HEALTHY MALE VOLUNTEERS","status":"WITHDRAWN","sponsor":"Pfizer","startDate":"2021-01-22","conditions":"Pharmacokinetics","enrollment":""},{"nctId":"NCT02364999","phase":"PHASE3","title":"A Comparative Study Of PF-06439535 Plus Paclitaxel-Carboplatin And Bevacizumab Plus Paclitaxel-Carboplatin Patients With Advanced Non-Squamous NSCLC","status":"COMPLETED","sponsor":"Pfizer","startDate":"2015-04","conditions":"Non-Small Cell Lung Cancer","enrollment":719}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Bevacizumab-Pfizer","genericName":"Bevacizumab-Pfizer","companyName":"Pfizer","companyId":"pfizer","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Bevacizumab is a monoclonal antibody that blocks vascular endothelial growth factor (VEGF), preventing tumor blood vessel formation and starving tumors of oxygen and nutrients. Used for Metastatic colorectal cancer, Metastatic non-small cell lung cancer, Metastatic breast cancer.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}